Logo image of RSLS

RESHAPE LIFESCIENCES INC (RSLS) Stock Fundamental Analysis

NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD

2.37  -0.05 (-2.07%)

After market: 2.45 +0.08 (+3.38%)

Fundamental Rating

2

Overall RSLS gets a fundamental rating of 2 out of 10. We evaluated RSLS against 187 industry peers in the Health Care Equipment & Supplies industry. While RSLS seems to be doing ok healthwise, there are quite some concerns on its profitability. RSLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RSLS has reported negative net income.
In the past year RSLS has reported a negative cash flow from operations.
In the past 5 years RSLS always reported negative net income.
RSLS had a negative operating cash flow in each of the past 5 years.
RSLS Yearly Net Income VS EBIT VS OCF VS FCFRSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -53.42%, RSLS is doing worse than 68.45% of the companies in the same industry.
Looking at the Return On Equity, with a value of -281.54%, RSLS is doing worse than 80.75% of the companies in the same industry.
Industry RankSector Rank
ROA -53.42%
ROE -281.54%
ROIC N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RSLS Yearly ROA, ROE, ROICRSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K 3K

1.3 Margins

RSLS has a Gross Margin of 63.74%. This is in the better half of the industry: RSLS outperforms 65.24% of its industry peers.
In the last couple of years the Gross Margin of RSLS has grown nicely.
The Profit Margin and Operating Margin are not available for RSLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
RSLS Yearly Profit, Operating, Gross MarginsRSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

4

2. Health

2.1 Basic Checks

RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RSLS has more shares outstanding
Compared to 5 years ago, RSLS has more shares outstanding
RSLS has a worse debt/assets ratio than last year.
RSLS Yearly Shares OutstandingRSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5K 10K 15K 20K 25K
RSLS Yearly Total Debt VS Total AssetsRSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RSLS has an Altman-Z score of -139.96. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -139.96, RSLS is doing worse than 97.86% of the companies in the same industry.
RSLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -139.96
ROIC/WACCN/A
WACC8.26%
RSLS Yearly LT Debt VS Equity VS FCFRSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.53 indicates that RSLS should not have too much problems paying its short term obligations.
The Current ratio of RSLS (1.53) is worse than 75.40% of its industry peers.
A Quick Ratio of 0.91 indicates that RSLS may have some problems paying its short term obligations.
RSLS has a Quick ratio of 0.91. This is amonst the worse of the industry: RSLS underperforms 80.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 0.91
RSLS Yearly Current Assets VS Current LiabilitesRSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

2

3. Growth

3.1 Past

RSLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.64%, which is quite impressive.
Looking at the last year, RSLS shows a very negative growth in Revenue. The Revenue has decreased by -13.93% in the last year.
RSLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.54% yearly.
EPS 1Y (TTM)93.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114%
Revenue 1Y (TTM)-13.93%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-42.75%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RSLS Yearly Revenue VS EstimatesRSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
RSLS Yearly EPS VS EstimatesRSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RSLS. In the last year negative earnings were reported.
Also next year RSLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RSLS Price Earnings VS Forward Price EarningsRSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RSLS Per share dataRSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RSLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (7/3/2025, 8:07:14 PM)

After market: 2.45 +0.08 (+3.38%)

2.37

-0.05 (-2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-12 2025-08-12
Inst Owners1.31%
Inst Owner Change442.55%
Ins Owners0.11%
Ins Owner Change0%
Market Cap1.75M
Analysts43.33
Price TargetN/A
Short Float %131.52%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)-212.11
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-6.05
FCFYN/A
OCF(TTM)-6.05
OCFYN/A
SpS9.7
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.42%
ROE -281.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.74%
FCFM N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
F-Score3
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 0.91
Altman-Z -139.96
F-Score3
WACC8.26%
ROIC/WACCN/A
Cap/Depr(3y)11.32%
Cap/Depr(5y)20.35%
Cap/Sales(3y)0.55%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114%
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.93%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-42.75%
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.15%
OCF growth 3YN/A
OCF growth 5YN/A